Reports & eBooks

Drug Pipeline & Clinical Update - May 2024

May 30, 2024

Capital Rx


  • One key new drug approval: Xolremdi™ capsules to tread WHIM syndrome
  • One notable expanded indication: Rinvoq® to treat psoriatic arthritis in patients >2yo
  • Two generic launches
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our May 2024 Monthly Drug Update!

Key New Drug Approvals

Xolremdi™ (mavorixafor) capsules

Approval Date: 04/26/2024 - CLICK HERE for the press release

Indication: Treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections, and myelokathexis) in patients 12 years of age and older

Cost*: $31,000 - $41,000 monthly

Key Considerations:

Notable Expanded Indications

Rinvoq® (upadacitinib) – expanded to treat psoriatic arthritis in patients 2 years of age and older

Generic Launches

EstroGel® (estradiol 0.06%) gel

Myrbetriq® (mirabegron ER 24hr 50 mg) tablet

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.


* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!